scholarly journals Detection of the Single-Session Complete Ablation Rate by Contrast-Enhanced Ultrasound during Ultrasound-Guided Laser Ablation for Benign Thyroid Nodules: A Prospective Study

2016 ◽  
Vol 2016 ◽  
pp. 1-8 ◽  
Author(s):  
Shuhua Ma ◽  
Ping Zhou ◽  
Xiaomin Wu ◽  
Shuangming Tian ◽  
Yongfeng Zhao
Keyword(s):  
Laser Ablation ◽  
Thyroid Nodules ◽  
Ablation Rate ◽  
Contrast Enhanced Ultrasound ◽  
Single Session ◽  
Ultrasound Guided ◽  
Complete Ablation ◽  
Contrast Enhanced ◽  
Benign Thyroid Nodules ◽  
Benign Thyroid

This study aimed to investigate the single-session complete ablation rate of ultrasound-guided percutaneous laser ablation (LA) for benign thyroid nodules. LA was performed in 90 patients with 118 benign thyroid nodules. Contrast-enhanced ultrasound (CEUS) was used to evaluate complete nodule ablation one day after ablation. Thyroid nodule volumes, thyroid functions, clinical symptoms and complications were evaluated 1, 3, 6, 12, and 18 months after ablation. Results showed that all benign thyroid nodules successfully underwent LA. The single-session complete ablation rates for nodules with maximum diameters ≤2 cm, 2-3 cm and ≥3 cm were 93.4%, 70.3% and 61.1%, respectively. All nodule volumes significantly decreased than that one day after ablation (P<0.05); at the final evaluation, the volume decreased from6.16±5.21 mL to0.05±0.01 mL. Thyroid functions did not show significant differences at one month after ablation compared with that before (P>0.05). Three patients had obvious pain during ablation; one (1.1%) had recurrent laryngeal nerve injury, but the voice returned to normal within 6 months after treatment. Thus, ultrasound-guided LA can effectively inactivate benign thyroid nodules. LA is a potentially viable minimally invasive treatment that offers good cosmetic effects.

scholarly journals Percutaneous, Ultrasound-guided Laser Ablation of Benign Thyroid Nodules: Results of 10-year Follow-up in 171 Patients

2021 ◽  
Author(s):  
Giovanni Gambelunghe ◽  
Elisa Stefanetti ◽  
Nicola Avenia ◽  
Pierpaolo De Feo
Keyword(s):  
Laser Ablation ◽  
Thyroid Nodules ◽  
Single Session ◽  
Ultrasound Guided ◽  
Prolonged Effect ◽  
Nodule Volume ◽  
Benign Thyroid Nodules ◽  
Benign Thyroid

Abstract Background Percutaneous, ultrasound-guided laser ablation is effective in nodular thyroid disease. The aim of this study was to evaluate the long-term (10-year) efficacy and safety of laser ablation in the treatment of benign thyroid nodules. Methods Between 2009 and 2010, 171 patients received a single session of laser ablation. Evaluation of nodule volume was performed before treatment, at 6 months, and every year. Results Technique efficacy was achieved in 92% of patients at 1 year. Median nodule volume significantly decreased from 16.7 mL (range: 11.0−97.0 mL) at baseline to 5.0 mL (range: 4.1−32.0 mL) at 1 year, a volume reduction ratio (VRR) of 68%. The benefit of the treatment was durable (p &lt; 0.001 vs baseline at all timepoints), with a VRR of 59% after 10 years. No cases of nodule regrowth &gt;50% were observed at 1 year, although such cases did occur after 4 years (n = 3; 1.7% of the overall cohort) and 7 years (n = 8; 4.7%). There were no further cases of regrowth beyond 7 years. When patients were stratified according to baseline nodule volume (&lt;15 mL, 15−25 mL, or &gt;25 mL), durable results were observed across all 3 categories, with the largest, most prolonged effect observed in patients with nodules &lt;15 mL. Treatment was well tolerated, with only minor, transient complications of fever and local pain, and 98% of patients willing to recommend the treatment. Conclusions Percutaneous, ultrasound-guided laser ablation of benign thyroid nodules provides long-term benefits and the treatment is well tolerated.

scholarly journals Reproducibility of Ablated Volume Measurement Is Higher with Contrast-Enhanced Ultrasound than with B-Mode Ultrasound after Benign Thyroid Nodule Radiofrequency Ablation—A Preliminary Study

2020 ◽  
Vol 9 (5) ◽  
pp. 1504 ◽  
Author(s):  
Simone Schiaffino ◽  
Francesca Serpi ◽  
Duccio Rossi ◽  
Valerio Ferrara ◽  
Ciriaco Buonomenna ◽  
...  
Keyword(s):  
Radiofrequency Ablation ◽  
Thyroid Nodules ◽  
Observer Agreement ◽  
Contrast Enhanced Ultrasound ◽  
Limits Of Agreement ◽  
Contrast Enhanced ◽  
The Mean ◽  
Preliminary Study ◽  
Benign Thyroid Nodules ◽  
Benign Thyroid

The reproducibility of contrast-enhanced ultrasound (CEUS) and standard B-mode ultrasound in the assessment of radiofrequency-ablated volume of benign thyroid nodules was compared. A preliminary study was conducted on consecutive patients who underwent radiofrequency ablation (RFA) of benign thyroid nodules between 2014 and 2016, with available CEUS and B-mode post-ablation checks. CEUS and B-mode images were retrospectively evaluated by two radiologists to assess inter- and intra-observer agreement in the assessment of ablated volume (Bland–Altman test). For CEUS, the mean inter-observer difference (95% limits of agreement) was 0.219 mL (-0.372–0.809 mL); for B-mode, the mean difference was 0.880 mL (-1.655–3.414 mL). Reproducibility was significantly higher for CEUS (85%) than for B-mode (27%). Mean intra-observer differences (95% limits of agreement) were 0.013 mL (0.803–4.097 mL) for Reader 1 and 0.031 mL (0.763–3.931 mL) for Reader 2 using CEUS, while they were 0.567 mL (-2.180–4.317 mL, Reader 1) and 0.759 mL (-2.584–4.290 mL, Reader 2) for B-mode. Intra-observer reproducibility was significantly higher for CEUS (96% and 95%, for the two readers) than for B-mode (21% and 23%). In conclusion, CEUS had higher reproducibility and inter- and intra-observer agreement compared to conventional B-mode in the assessment of radiofrequency-ablated volume of benign thyroid nodules.

scholarly journals Percutaneous Ultrasound-Guided Laser Ablation with Contrast-Enhanced Ultrasonography for Hyperfunctioning Parathyroid Adenoma: A Preliminary Case Series

2015 ◽  
Vol 2015 ◽  
pp. 1-6 ◽  
Author(s):  
Tianan Jiang ◽  
Fen Chen ◽  
Xiang Zhou ◽  
Ying Hu ◽  
Qiyu Zhao
Keyword(s):  
Laser Ablation ◽  
Parathyroid Adenoma ◽  
Serum Calcium ◽  
Treatment Success ◽  
Case Series ◽  
Contrast Enhanced Ultrasound ◽  
Ultrasound Guided ◽  
Complete Ablation ◽  
Contrast Enhanced ◽  
Serum Pth

The study was to evaluate the safety and effectiveness of ultrasound-guided percutaneous laser ablation (pLA) as a nonsurgical treatment for primary parathyroid adenoma. Surgery was contraindicated in, or refused by, the included patients. No lesion enhancement on contrast-enhanced ultrasound immediately after pLA was considered “complete ablation.” Nodule size, serum calcium, and parathyroid hormone level were compared before and after pLA. Complete ablation was achieved in all 21 patients with 1 (n=20) or 2 (n=1) sessions. Nodule volume decreased from0.93±0.58 mL at baseline to0.53±0.38and0.48±0.34 mL at 6 and 12 months after pLA (P<0.05). At 1 day, 6 months, and 12 months after pLA, serum PTH decreased from15.23±3.00 pmol/L at baseline to7.41±2.79,6.95±1.78, and6.90±1.46 pmol/L, serum calcium decreased from3.77±0.77 mmol/L at baseline to2.50±0.72,2.41±0.37, and2.28±0.26 mmol/L, respectively (P<0.05). At 12 months, treatment success (normalization of PTH and serum calcium) was achieved in 81%. No serious complications were observed. Ultrasound-guided pLA with contrast-enhanced ultrasound is a viable alternative to surgery for primary parathyroid adenoma.

Ultrasound-guided percutaneous laser ablation in treating symptomatic solid benign thyroid nodules: Our experience in 45 patients

Head & Neck ◽  
2015 ◽  
Vol 38 (5) ◽  
pp. 677-682 ◽  
Author(s):  
Gaetano Achille ◽  
Stefania Zizzi ◽  
Enrico Di Stasio ◽  
Alberto Grammatica ◽  
Luciano Grammatica
Keyword(s):  
Laser Ablation ◽  
Thyroid Nodules ◽  
Ultrasound Guided ◽  
Percutaneous Laser Ablation ◽  
Benign Thyroid Nodules ◽  
Benign Thyroid
Sign in / Sign up

Export Citation Format

Share Document